AU2017366674B2 - Fusion proteins for selectively depleting antigen-specific antibodies - Google Patents

Fusion proteins for selectively depleting antigen-specific antibodies Download PDF

Info

Publication number
AU2017366674B2
AU2017366674B2 AU2017366674A AU2017366674A AU2017366674B2 AU 2017366674 B2 AU2017366674 B2 AU 2017366674B2 AU 2017366674 A AU2017366674 A AU 2017366674A AU 2017366674 A AU2017366674 A AU 2017366674A AU 2017366674 B2 AU2017366674 B2 AU 2017366674B2
Authority
AU
Australia
Prior art keywords
seq
seldeg
antigen
fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017366674A
Other languages
English (en)
Other versions
AU2017366674A1 (en
Inventor
Venkata Siva Charan DEVANABOYINA
Elizabeth Sally Ward OBER
Raimund Johannes OBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of AU2017366674A1 publication Critical patent/AU2017366674A1/en
Application granted granted Critical
Publication of AU2017366674B2 publication Critical patent/AU2017366674B2/en
Priority to AU2025202131A priority Critical patent/AU2025202131A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017366674A 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies Active AU2017366674B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202131A AU2025202131A1 (en) 2016-12-02 2025-03-25 Fusion proteins for selectively depleting antigen-specific antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429367P 2016-12-02 2016-12-02
US62/429,367 2016-12-02
PCT/US2017/064186 WO2018102668A1 (en) 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202131A Division AU2025202131A1 (en) 2016-12-02 2025-03-25 Fusion proteins for selectively depleting antigen-specific antibodies

Publications (2)

Publication Number Publication Date
AU2017366674A1 AU2017366674A1 (en) 2019-06-20
AU2017366674B2 true AU2017366674B2 (en) 2025-01-02

Family

ID=62242041

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017366674A Active AU2017366674B2 (en) 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies
AU2025202131A Pending AU2025202131A1 (en) 2016-12-02 2025-03-25 Fusion proteins for selectively depleting antigen-specific antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202131A Pending AU2025202131A1 (en) 2016-12-02 2025-03-25 Fusion proteins for selectively depleting antigen-specific antibodies

Country Status (7)

Country Link
US (2) US11459396B2 (enExample)
EP (1) EP3548073A4 (enExample)
JP (3) JP7295799B2 (enExample)
CN (1) CN110799210A (enExample)
AU (2) AU2017366674B2 (enExample)
CA (1) CA3045797A1 (enExample)
WO (1) WO2018102668A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136455A1 (en) 2017-01-17 2018-07-26 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
CA3192748A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for increasing efficacy of viral vectors
WO2022063887A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
AR123581A1 (es) 2020-09-23 2022-12-21 Ablevia Biotech Gmbh Compuesto para el secuestro de anticuerpos anti peg no deseables en un paciente
IL301332A (en) 2020-09-23 2023-05-01 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230381328A1 (en) 2020-09-24 2023-11-30 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
CA3246627A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh COMPOUND FOR INCREASING THE EFFECTIVENESS OF ONCOLYTIC VIRUSES
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
EP4608864A1 (en) * 2022-10-26 2025-09-03 Amgen Inc. Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
CN120624489B (zh) * 2025-08-18 2025-12-02 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044329A2 (en) * 2000-11-30 2002-06-06 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2012150319A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016414A2 (en) * 2000-08-22 2002-02-28 Micromet Ag Composition for the elimination of autoreactive b-cells
JP5785493B2 (ja) * 2008-09-17 2015-09-30 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
ES2608835T3 (es) * 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
CA2934644C (en) * 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
US20170334962A1 (en) 2016-05-19 2017-11-23 Texas A&M University System FcRn-TARGETED ANTIGEN FUSION PROTEINS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044329A2 (en) * 2000-11-30 2002-06-06 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2012150319A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BATTAINI, F. ET AL.: "Antibody response after vaccination with antigen-pulsed dendritic cells", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 19, no. 3, 1 July 2004 (2004-07-01), pages 213 - 220, XP009191243, ISSN: 0393-6155 *
CHALLA, D. ET AL.: "Antigen dynamics govern the induction of CD 4+ T cell tolerance during autoimmunity", JOURNAL OF AUTOIMMUNITY, vol. 72, 25 May 2016 (2016-05-25), pages 84 - 94, XP029651618 *
HA, J-H. ET AL.: "Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins", FRONTIERS IN IMMUNOLOGY, vol. 7, 6 October 2016 (2016-10-06), pages 1 - 16, XP055377975 *
MANN, J. ET AL.: "Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen", JOURNAL OF CONTROLLED RELEASE, vol. 158, 2012, pages 240 - 249, XP055490795 *
SAITO, Y. ET AL, PROC. NATL. ACAD. SCI. USA., vol. 92, 1995, pages 10227 - 10231, XP002933518 *

Also Published As

Publication number Publication date
EP3548073A4 (en) 2020-07-22
US12404339B2 (en) 2025-09-02
AU2017366674A1 (en) 2019-06-20
EP3548073A1 (en) 2019-10-09
US20230087965A1 (en) 2023-03-23
JP2025131743A (ja) 2025-09-09
JP2023113894A (ja) 2023-08-16
JP7295799B2 (ja) 2023-06-21
CN110799210A (zh) 2020-02-14
CA3045797A1 (en) 2018-06-07
AU2025202131A1 (en) 2025-04-10
US20200031948A1 (en) 2020-01-30
US11459396B2 (en) 2022-10-04
JP7832913B2 (ja) 2026-03-18
WO2018102668A1 (en) 2018-06-07
JP2020500885A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
US12404339B2 (en) Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies
US12054545B2 (en) Heterodimeric antibodies that bind somatostatin receptor 2
JP2022185021A (ja) 多価多重特異性ｏｘ４０結合融合タンパク質
CA2899830C (en) Binding molecules for bcma and cd3
CN105189557A (zh) 四价双特异性抗体
CN109963869A (zh) 与经改造的Fc构建体相关的组合物和方法
CA2849196A1 (en) Binding molecules for bcma and cd3
JP2025508827A (ja) 抗ｃｄ２８×抗ｐｓｍａ抗体
CA3193273A1 (en) Methods and compositions to treat autoimmune diseases and cancer
JP2026048845A (ja) メソテリン結合タンパク質及びその使用
KR20260010770A (ko) 항-cd28 × 항-trop2 항체
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
US20260035435A1 (en) Approaches for the selective depletion of pla2r-specific antibodies
WO2026064598A1 (en) Approaches for the selective depletion of adamts13-specific antibodies
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
WO2024263558A1 (en) Dual transporters and methods of use
CN118119402A (zh) 工程化抗her2双特异性蛋白
HK40007765A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)